SavedAdd your journal

Journals / Eklem Hastalıkları ve Cerrahisi Dergisi (Eski Adı: Artroplasti Artroskopik Cerrahi Derg.) / 2014 / Cilt: 25 - Sayı: 1

Uzun süreli alendronat tedavisi gören hastalarda femoral yetersizlik kırıkları iyileşir mi?

Do atypical femoral fractures in patients with prolonged alendronate treatment heal?

Mehmet ÇETİNKAYA
Cemalettin KUNAT
Yiğit KAPTAN
Akif M. ÖZTÜRK
O. Şahap ATİK
Pages
52–55
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, we describe two patients onlong-term alendronate therapy which were treated for atypicalfemoral fractures healed with surgical treatment plus calcium,vitamin D support, and alendronate discontinuation.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Osteoporosis, which is a major health problem, may have anadverse impact on the economic status of the society and thequality of the life of the patients.
📊
Key Findings & Data:Long-term alendronate use maycause an increased susceptibility to fractures with an increasedrisk of delayed union.
💡
Conclusion & Impact:In this article, we describe two patients onlong-term alendronate therapy which were treated for atypicalfemoral fractures healed with surgical treatment plus calcium,vitamin D support, and alendronate discontinuation.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Osteoporosis, which is a major health problem, may have anadverse impact on the economic status of the society and thequality of the life of the patients. Long-term alendronate use maycause an increased susceptibility to fractures with an increasedrisk of delayed union. In this article, we describe two patients onlong-term alendronate therapy which were treated for atypicalfemoral fractures healed with surgical treatment plus calcium,vitamin D support, and alendronate discontinuation.

Özet

Osteoporoz, toplumun ekonomik durumunda ve hastaların yaşam kalitesinde olumsuz etki yaratabilen önemli bir sağlık sorunudur. Uzun süreli alendronat kullanımı, kırığa yatkınlığı ve geç kaynama riskini artırabilir. Bu yazıda uzun süredir alendronat almakta olan ve atipik femur kırıklarının cerrahi tedaviye ek olarak kalsiyum, D vitamini desteğive alendronat alımının durdurulması ile iyileşen iki hasta bildirildi.

🔖

Cite This Article

ÇETİNKAYA, M., KUNAT, C., KAPTAN, Y., ÖZTÜRK, A. M., ATİK, O. Ş. (2022). Uzun süreli alendronat tedavisi gören hastalarda femoral yetersizlik kırıkları iyileşir mi?. Eklem Hastalıkları ve Cerrahisi Dergisi (Eski Adı: Artroplasti Artroskopik Cerrahi Derg.), Cilt: 25 - Sayı: 1, 52–55. https://ajindex.com/articles/498596

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Gül O, Atik OS, Erdoğan D, Göktaş G, Elmas C. Transmission and scanning electron microscopy confirm that bone microstructure is similar in osteopenic and osteoporotic patients. Eklem Hastalik Cerrahisi 2013;24:126-32
  2. Atik OS, Gunal I, Korkusuz F. Burden of osteoporosis. Clin Orthop Relat Res 2006;443:19-24
  3. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301
  4. Atik OS, Suluova F, Görmeli G, Yildirim A, Ali AKh. Insufficiency femoral fractures in patients undergoing prolonged alendronate therapy. Eklem Hastalik Cerrahisi 2010;21:56-9
  5. Weil YA, Rivkin G, Safran O, Liebergall M, Foldes AJ. The outcome of surgically treated femur fractures associated with long-term bisphosphonate use. J Trauma 2011;71:186-90
  6. Grady MK, Watson JT, Cannada LK. Treatment of femoral fracture nonunion after long-term bisphosphonate use. Orthopedics 2012;35:e991-5
  7. Stepan JJ, Burr DB, Pavo I, Sipos A, Michalska D, Li J, et al. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 2007;41:378-85
  8. Schneider JP. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. Geriatrics 2009;64:18-23
  9. Edwards BJ, Bunta AD, Lane J, Odvina C, Rao DS, Raisch DW, et al. Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project. J Bone Joint Surg [Am] 2013;95:297-307.